- Home
- AUDC vs CTNM Comparison
AUDC vs CTNM Comparison
Compare AUDC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- CTNM
- Stock Information
- Founded
- AUDC 1992
- CTNM 2009
- Country
- AUDC Israel
- CTNM United States
- Employees
- AUDC N/A
- CTNM N/A
- Industry
- AUDC Telecommunications Equipment
- CTNM
- Sector
- AUDC Utilities
- CTNM
- Exchange
- AUDC Nasdaq
- CTNM Nasdaq
- Market Cap
- AUDC 282.4M
- CTNM 248.7M
- IPO Year
- AUDC 1999
- CTNM 2024
- Fundamental
- Price
- AUDC $9.62
- CTNM $11.21
- Analyst Decision
- AUDC Buy
- CTNM Strong Buy
- Analyst Count
- AUDC 3
- CTNM 5
- Target Price
- AUDC $11.67
- CTNM $22.20
- AVG Volume (30 Days)
- AUDC 106.0K
- CTNM 201.6K
- Earning Date
- AUDC 11-05-2025
- CTNM 11-05-2025
- Dividend Yield
- AUDC 4.15%
- CTNM N/A
- EPS Growth
- AUDC 3.22
- CTNM N/A
- EPS
- AUDC 0.46
- CTNM N/A
- Revenue
- AUDC $243,249,000.00
- CTNM N/A
- Revenue This Year
- AUDC $2.52
- CTNM N/A
- Revenue Next Year
- AUDC $1.74
- CTNM N/A
- P/E Ratio
- AUDC $21.10
- CTNM N/A
- Revenue Growth
- AUDC N/A
- CTNM N/A
- 52 Week Low
- AUDC $7.70
- CTNM $3.35
- 52 Week High
- AUDC $12.72
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- AUDC 45.64
- CTNM 55.51
- Support Level
- AUDC $9.62
- CTNM $10.65
- Resistance Level
- AUDC $9.86
- CTNM $12.14
- Average True Range (ATR)
- AUDC 0.23
- CTNM 0.97
- MACD
- AUDC -0.04
- CTNM -0.23
- Stochastic Oscillator
- AUDC 21.50
- CTNM 32.20
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.